InDex Pharmaceuticals Holding AB (publ) interim report January – September 2022
The Board has appointed Jenny Sundqvist as new CEO“It has been an eventful quarter, and we are very pleased to welcome Jenny Sundqvist as the new CEO of InDex. Patient recruitment for the phase III study CONCLUDE with cobitolimod is underway and although the study has had a slower start-up than expected, a number of clinics have been very active in enrolling patients. We look forward to an exciting winter where we continue to take measures that we believe will have a positive effect on the recruitment rate going forward”, says Johan Giléus, acting CEO of InDex Pharmaceuticals. Period